MedImmune, the global biologics research and development arm of AstraZeneca, is hosting aone-​​day Translational Science Forum in the Bay Area, gathering academic institutions, industry leaders, and other experts in the drug development ecosystem to assess a critical question: How are digital technologies transforming patients’ and drug developers’ understanding of diseases and treatment options?

As the “one-​size-​fit-​all” approach to drug development becomes a thing of the past, the Forum will address:

How can scientists successfully embrace the new patient centric drug development paradigm and put patients first?

How can scientists get novel insights into diseases and better predict disease progressions and outcomes by leveraging data science, bioinformatics, and digital tools (such as machine learning and AI)?

This forum will highlight digital transformation in various stages of the drug development process and showcase advances in technology that brings patient centricity to reality.

The Translational Science Forum will provide attendees an opportunity to:

Hear PRESENTATIONSfrom leading and forward-​thinking experts;

Interact and engage experts during extended Q&As and RECEPTION sessions;

NETWORK and COLLABORATE with digital health experts from the Bay Area biotech hub and surrounding areas.